Market Place
Sourcing Support
Adamis Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
07 Sep 2023 //
GLOBENEWSWIRE
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals
07 Sep 2023 //
CONTRACT PHARMA
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results
21 Aug 2023 //
GLOBENEWSWIRE
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
04 Aug 2023 //
GLOBENEWSWIRE
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
02 Aug 2023 //
GLOBENEWSWIRE
Adamis to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
28 Jul 2023 //
GLOBENEWSWIRE
Adamis Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
26 Jun 2023 //
GLOBENEWSWIRE
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
25 May 2023 //
GLOBENEWSWIRE
Adamis Pharmaceuticals Announces Reverse Stock Split
19 May 2023 //
GLOBENEWSWIRE
Adamis Pharmaceuticals Reports 1Q 2023 FYR Results and Provides Corporate Update
15 May 2023 //
GLOBENEWSWIRE
Adamis Pharmaceuticals Schedules 1Q 2023 FYR Conference Call
08 May 2023 //
GLOBENEWSWIRE
Adamis Reports Full Year 2022 Financial Results and Provides Corporate Update
16 Mar 2023 //
GLOBENEWSWIRE
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
14 Mar 2023 //
PRESS RELEASE
Adamis Schedules Fourth Quarter and Full Year 2022 Financial Results Conference
14 Mar 2023 //
PRESS RELEASE
Latest biotech merger sees aimless Adamis snapped up by DMK
28 Feb 2023 //
FIERCE BIOTECH
Adamis Pharma and DMK Pharmaceuticals Announce Agreement and Plan of Merger
27 Feb 2023 //
GLOBENEWSWIRE
Nasdaq Grants Adamis Pharma Request for Extension for Listing Requirements
22 Feb 2023 //
GLOBENEWSWIRE
Adamis, Harpoon, Neoleukin and Tricida grow biotech layoff wave
15 Nov 2022 //
FIERCEBIOTECH
Adamis Pharmaceuticals Reports 3Q 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Adamis Schedules 3Q 2022 Financial Results Conference Call and Corporate Update
07 Nov 2022 //
GLOBENEWSWIRE
Product sales, mergers and layoffs may be in the cards at Adamis
04 Oct 2022 //
FIERCEPHARMA
Adamis Announces Review of Strategic Alternatives
03 Oct 2022 //
GLOBENEWSWIRE
Adamis considers sale of company as part of strategic alternatives review
03 Oct 2022 //
SEEKINGALPHA
Adamis’ shares nosedive as sole clinical-stage asset flunks COVID-19 trial
22 Sep 2022 //
FIERCEBIOTECH
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive
21 Sep 2022 //
GLOBENEWSWIRE
Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol
13 Sep 2022 //
PRESS RELEASE
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
12 Aug 2022 //
GLOBENEWSWIRE
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals
29 Jul 2022 //
GLOBENEWSWIRE
Adamis Pharmaceuticals Issues Letter to Stockholders
21 Jul 2022 //
GLOBENEWSWIRE
Adamis to continue Phase II/III trial of Tempol for Covid-19
02 Jun 2022 //
CLINICALTRIALSARENA
Adamis Pharmaceuticals Provides Update on Study Assessing Tempol for COVID-19
01 Jun 2022 //
GLOBENEWSWIRE
Adamis Appoints Vickie Reed to Board of Directors
26 May 2022 //
GLOBENEWSWIRE
Adamis Pharma Announces Leadership Transition for Innovation and Growth
18 May 2022 //
GLOBENEWSWIRE
Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Enforcement Report - Week of April 13, 2022
13 Apr 2022 //
FDA
Adamis Pharma Reports Full Year 2021 Financial Results
31 Mar 2022 //
GLOBENEWSWIRE
Adamis Pharma Schedules Q4 and Full Year 2021 Financial Results Conference Call
24 Mar 2022 //
GLOBENEWSWIRE
Adamis recalls epinephrine after reports of glitches
24 Mar 2022 //
FIERCEPHARMA
Adamis Pharma Announces Results of Tempol in Omicron Virus Challenge
22 Mar 2022 //
GLOBENEWSWIRE
Adamis Pharma Issues Nationwide Voluntary Recall of SYMJEPI Injection
21 Mar 2022 //
GLOBENEWSWIRE
Adamis Pharma Provides Update on Clinical Study Assessing Tempol for COVID-19
14 Mar 2022 //
GLOBENEWSWIRE
Adamis Pharma Clinical Study Assessing Tempol Surpasses Enrollment Expectations
28 Feb 2022 //
GLOBENEWSWIRE
Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Feb 2022 //
GLOBENEWSWIRE
Adamis Gives Enrollment Update of Subjects in Phase 2/3 of Tempol for COVID-19
07 Feb 2022 //
GLOBENEWSWIRE
Adamis seeks FDA fast-track designation for Tempol against Covid-19
11 Jan 2022 //
PHARMACEUTICAL-TECHNOLOGY
Adamis Pharma Submits Fast Track Application for Tempol in COVID-19
10 Jan 2022 //
GLOBENEWSWIRE
Adamis Pharmaceuticals Regains Compliance with NASDAQ
23 Nov 2021 //
GLOBENEWSWIRE
Adamis Announces Q3 2021 Financial Results and Provides Corporate Update
22 Nov 2021 //
GLOBENEWSWIRE
Adamis nabs approval of high-dose naloxone injection after two CRLs
19 Oct 2021 //
ENDPTS
Adamis begins subject dosing in Phase II/III Covid-19 treatment trial
03 Sep 2021 //
CLINICAL TRAIL ARENA
Adamis Doses 1st Patient in Phase 2/3 Clinical Trial for Tempol in COVID-19
02 Sep 2021 //
GLOBENEWSWIRE
Adamis Appoints David C. Benedicto as CFO and Other Events
24 Aug 2021 //
GLOBENEWSWIRE
Adamis: "Tempol Inhibits Multiple Cytokines from COVID-19 Patient’s Cells"
24 Aug 2021 //
GLOBENEWSWIRE
Adamis Announces Agreement to Sell Portion of US Compounding Business
04 Aug 2021 //
GLOBENEWSWIRE
Adamis Urges Stockholders to Vote to Reelect the Company’s Board of Directors
13 Jul 2021 //
BUSINESSWIRE
Adamis Sends Letter to Stockholders to Address Jerald A. Hamma+C63:D149nn
01 Jul 2021 //
BUSINESSWIRE
